Answers are grounded in this paper and cite their sources.
The complexity of Eph signaling is a challenge for the definition of clear targets for cancer treatment. Nevertheless, numerous drugs that target EphA2 and EphB4 are currently in clinical trials. However, some Eph targeted drugs also inhibit other tyrosine kinases, so it is unclear to what extent the targeting of Eph receptors contributes to their efficacy. Future research is warranted for an improved understanding of the full network in which Eph receptors function. This will be critical for the improvement of the anticancer effects of drugs that target the Eph receptors.
No takes yet. Share an insight, caveat, or question.
Buckens et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: